Candel Therapeutics, Inc.

As of June 17, 2025, the technical trend has shifted to a bearish stance, supported by bearish MACD, Bollinger Bands, and moving averages, despite a bullish weekly RSI.

Candel Therapeutics, Inc. is a micro-cap company in the miscellaneous industry, reporting a net profit of $7 million for Q1 2025 and a market cap of $247.51 million. Key metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -45.06%.

As of Jun 18, Candel Therapeutics, Inc. has a market capitalization of 247.51 million and reported net sales of 0.00 million with a net profit of -39.58 million over the last four quarters. Shareholder's funds were 66.33 million, and total assets were 107.14 million as of Dec 24.